Version 2 2021-08-02, 19:39Version 2 2021-08-02, 19:39
Version 1 2021-08-02, 16:11Version 1 2021-08-02, 16:11
journal contribution
posted on 2021-08-02, 19:39authored byColin
D. Douglas, Lia Grandinetti, Nicole M. Easton, Oliver P. Kuehm, Joshua A. Hayden, Meghan C. Hamilton, Martin St. Maurice, Stephen L. Bearne
o-Carbonyl arylboronic acids such as 2-formylphenylboronic
acid (2-FPBA) are employed in biocompatible conjugation reactions
with the resulting iminoboronate adduct stabilized by an intramolecular
N–B interaction. However, few studies have utilized these reagents
as active site-directed enzyme inhibitors. We show that 2-FPBA is
a potent reversible, slow-onset inhibitor of mandelate racemase (MR),
an enzyme that has served as a valuable paradigm for understanding
enzyme-catalyzed abstraction of an α-proton from a carbon acid
substrate with a high pKa. Kinetic analysis
of the progress curves for the slow onset of inhibition of wild-type
MR using a two-step kinetic mechanism gave Ki and Ki* values of 5.1 ±
1.8 and 0.26 ± 0.08 μM, respectively. Hence, wild-type
MR binds 2-FPBA with an affinity that exceeds that for the substrate
by ∼3000-fold. K164R MR was inhibited by 2-FPBA, while K166R
MR was not inhibited, indicating that Lys 166 was essential for inhibition.
Unexpectedly, mass spectrometric analysis of the NaCNBH3-treated enzyme–inhibitor complex did not yield evidence of
an iminoboronate adduct. 11B nuclear magnetic resonance
spectroscopy of the MR·2-FPBA complex indicated that the boron
atom was sp3-hybridized (δ 6.0), consistent with
dative bond formation. Surprisingly, X-ray crystallography revealed
the formation of an Nζ–B dative bond between
Lys 166 and 2-FPBA with intramolecular cyclization to form a benzoxaborole,
rather than the expected iminoboronate. Thus, when o-carbonyl arylboronic acid reagents are employed to modify proteins,
the structure of the resulting product depends on the protein architecture
at the site of modification.